Tessa Therapeutics Completes Us$126 Million Financing Led By Polaris Partners

Jun 09, 2022•over 3 years ago

Amount Raised

$126 Million

Description

Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the close of a US$126 million Series A financing round. Polaris Partners led the financing with participation from existing investors, including Temasek, EDBI, Heliconia Capital and Heritas Capital. In conjunction with the financing, Amy Schulman and Darren Carroll, Managing Partners at Polaris Partners, have joined Tessa’s Board of Directors.

Company Information

Company

Tessa

About

The platform overcomes toxicity challenges common to “off the shelf” cell therapies such as Graft vs Host Disease (GVHD) by using allogeneic Virus specific T-cells (VSTs) augmented with CD30-CAR. Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility. The multibillion-dollar firm manages specialty and diversified funds in healthcare and technology with investments across all stages. “Tessa is at an exciting point with two differentiated clinical-stage programs pursuing novel approaches for the treatment of CD30-positive lymphomas.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Tessa Therapeutics Completes Us$126 Million Financing Led By Polaris Partners

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information